CU24734B1 - Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias - Google Patents

Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Info

Publication number
CU24734B1
CU24734B1 CU2021000021A CU20210021A CU24734B1 CU 24734 B1 CU24734 B1 CU 24734B1 CU 2021000021 A CU2021000021 A CU 2021000021A CU 20210021 A CU20210021 A CU 20210021A CU 24734 B1 CU24734 B1 CU 24734B1
Authority
CU
Cuba
Prior art keywords
vaccine compositions
treatment
growth factors
inflammatory diseases
hematopoietic growth
Prior art date
Application number
CU2021000021A
Other languages
English (en)
Other versions
CU20210021A7 (es
Inventor
Morales Dasha Fuentes
Valcarcel Jesus Ramón Galvez
Dávila Agustín Bienvenido Lage
Naranjo Nuris Ledón
Medianilla Armando López
Alfaro Oscar Otero
Yáñez Karla Pereira
Martínez Dayana Pérez
Dorantes Gertrudis Rojas
Hernandez Danay Saavedra
Sosa Alexa Silva
Formigo Gisela María Suárez
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2021000021A priority Critical patent/CU24734B1/es
Priority to PCT/CU2022/050002 priority patent/WO2022207016A1/es
Priority to BR112023019112A priority patent/BR112023019112A2/pt
Priority to CN202280025278.7A priority patent/CN117120079A/zh
Priority to EP22718850.5A priority patent/EP4316510A1/en
Priority to KR1020237037217A priority patent/KR20230163506A/ko
Priority to MX2023011509A priority patent/MX2023011509A/es
Priority to CA3213763A priority patent/CA3213763A1/en
Priority to AU2022251604A priority patent/AU2022251604B2/en
Priority to US18/285,011 priority patent/US20240374695A1/en
Priority to JP2023560805A priority patent/JP2024512762A/ja
Priority to ARP220100643A priority patent/AR125149A1/es
Priority to TW111110599A priority patent/TW202302623A/zh
Publication of CU20210021A7 publication Critical patent/CU20210021A7/es
Priority to CONC2023/0014267A priority patent/CO2023014267A2/es
Publication of CU24734B1 publication Critical patent/CU24734B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con la rama de la Biotecnología y la Medicina. Específicamente describe composiciones vacunales terapéuticas capaces de producir una reacción autoinmune contra factores de crecimiento hematopoyéticos como el G-SCF y/o GM-CSF unidas por conjugación química o fusión a otras moléculas o partes de ella. Dichas composiciones vacunales son útiles en el tratamiento de enfermedades inflamatorias, en especial donde ocurra una elevación patológica de neutrófilos circulantes.</p>
CU2021000021A 2021-03-30 2021-03-30 Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias CU24734B1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CU2021000021A CU24734B1 (es) 2021-03-30 2021-03-30 Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
CA3213763A CA3213763A1 (en) 2021-03-30 2022-03-16 Vaccine compositions depleting hematopoietic growth factors for the treatment of inflammatory diseases
AU2022251604A AU2022251604B2 (en) 2021-03-30 2022-03-16 Vaccine compositions depleting hematopoietic growth factors for the treatment of inflammatory diseases
CN202280025278.7A CN117120079A (zh) 2021-03-30 2022-03-16 用于治疗炎性疾病的造血生长因子耗竭疫苗组合物
EP22718850.5A EP4316510A1 (en) 2021-03-30 2022-03-16 Vaccine compositions depleting hematopoietic growth factors for the treatment of inflammatory diseases
KR1020237037217A KR20230163506A (ko) 2021-03-30 2022-03-16 염증성 질병 치료용 조혈 성장 인자를 고갈시키는 백신 조성물
MX2023011509A MX2023011509A (es) 2021-03-30 2022-03-16 Composiciones vacunales depletantes de factores de crecimiento hematopoyeticos para el tratamiento de enfermedades inflamatorias.
PCT/CU2022/050002 WO2022207016A1 (es) 2021-03-30 2022-03-16 Composiciones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
BR112023019112A BR112023019112A2 (pt) 2021-03-30 2022-03-16 Composições de vacinas depletantes de fatores de crescimento hematopoiético para o tratamento de doenças inflamatórias
US18/285,011 US20240374695A1 (en) 2021-03-30 2022-03-16 Vaccine compositions depleting hematopoietic growth factors for the treatment of inflammatory diseases
JP2023560805A JP2024512762A (ja) 2021-03-30 2022-03-16 炎症性疾患の治療のための造血増殖因子枯渇ワクチン組成物
ARP220100643A AR125149A1 (es) 2021-03-30 2022-03-18 Composiciones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
TW111110599A TW202302623A (zh) 2021-03-30 2022-03-22 用於治療發炎性疾病之造血生長因子耗盡之疫苗組成物
CONC2023/0014267A CO2023014267A2 (es) 2021-03-30 2023-10-24 Composiciones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2021000021A CU24734B1 (es) 2021-03-30 2021-03-30 Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Publications (2)

Publication Number Publication Date
CU20210021A7 CU20210021A7 (es) 2022-11-07
CU24734B1 true CU24734B1 (es) 2025-02-07

Family

ID=81387253

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000021A CU24734B1 (es) 2021-03-30 2021-03-30 Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Country Status (14)

Country Link
US (1) US20240374695A1 (es)
EP (1) EP4316510A1 (es)
JP (1) JP2024512762A (es)
KR (1) KR20230163506A (es)
CN (1) CN117120079A (es)
AR (1) AR125149A1 (es)
AU (1) AU2022251604B2 (es)
BR (1) BR112023019112A2 (es)
CA (1) CA3213763A1 (es)
CO (1) CO2023014267A2 (es)
CU (1) CU24734B1 (es)
MX (1) MX2023011509A (es)
TW (1) TW202302623A (es)
WO (1) WO2022207016A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2139756A1 (en) * 1992-07-08 1994-01-20 Eric M. Bonnem Use of gm-csf as a vaccine adjuvant
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
WO2010124163A2 (en) 2009-04-23 2010-10-28 Theraclone Sciences, Inc. Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
EP3580236A4 (en) * 2017-02-07 2020-12-09 ME Therapeutics Inc. ANTI-G-CSF ANTIBODIES AND ASSOCIATED USES
JP7320498B2 (ja) 2017-10-02 2023-08-03 ヒューマニジェン，インコーポレイテッド Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
WO2019178645A1 (en) 2018-03-23 2019-09-26 Csl Limited Method of treating asthma
US20220220209A1 (en) 2018-12-04 2022-07-14 CSL Innovation Pty Ltd Method of treating neutrophilic conditions

Also Published As

Publication number Publication date
AU2022251604B2 (en) 2025-11-27
EP4316510A1 (en) 2024-02-07
CA3213763A1 (en) 2022-10-06
KR20230163506A (ko) 2023-11-30
CN117120079A (zh) 2023-11-24
AR125149A1 (es) 2023-06-14
CO2023014267A2 (es) 2024-02-05
CU20210021A7 (es) 2022-11-07
US20240374695A1 (en) 2024-11-14
BR112023019112A2 (pt) 2023-10-24
WO2022207016A1 (es) 2022-10-06
MX2023011509A (es) 2023-10-04
AU2022251604A1 (en) 2023-10-26
TW202302623A (zh) 2023-01-16
JP2024512762A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
MX342764B (es) Composiciones y metodos para la distribucion selectiva de moleculas de oligonucleotidos a tipos especificos de neuronas.
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
ECSP23096498A (es) Restos de administración terapéutica novedosos y usos de estos
CR11817A (es) Anticuerpos anti-factor d humanizados y sus usos
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
AR092027A1 (es) Anticuerpos biespecificos anti-vegf/anti-ang-2 y su utilizacion en el tratamiento de enfermedades vasculares oculares
EP2568996A4 (en) INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC AND ANTIBODY COMPOSITIONS IN CONNECTION WITH PROTEIN FRAGMENTS OF PHENYLALANYL BETA-TRNA SYNTHETASES
PH12014502524B1 (en) Carboxylic acid compounds
EA201400871A1 (ru) Способ доставки нуклеиновых кислот с разделением, их композиции и использование
BR112015023084A2 (pt) anticorpo anti-cd25 monoclonal ou um fragmento ligante anti-cd25 de um anticorpo monoclonal, conjugado de anticorpo-droga, composição farmacêutica, ácido nucleico, vetor, célula hospedeira procariota e eucariota, método para a produção de um anticorpo anti-cd25 ou fragmento ligante anti-cd25, e, uso de um anticorpo anti-cd25 monoclonal de um conjugado anticorpo-droga ou de uma composição farmacêutica
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
BR112022015572A2 (pt) Anticorpo, composição, composição farmacêutica, anticorpo para uso como um medicamento, métodos para tratar uma doença e para produzir um anticorpo, ácido nucléico, um ou mais ácidos nucléicos, célula, e, kit de partes
BR112015018203A2 (pt) Anti-corpos biespecíficos anti-tnf-anti-il-17
UY35250A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos.
CL2023002099A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
MX2022013362A (es) Composiciones para tratar cancer con mutaciones de kras y usos de las mismas.
MX2022016589A (es) O-antigeno de klebsiella pneumoniae.
BR112018004257A2 (pt) composto e composição farmacêutica
CU24734B1 (es) Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias
ECSP24047821A (es) Compuestos que contienen heteroátomos y usos de estos
BR112022016010A2 (pt) Formulações de anticorpos anti-tslp humanos e métodos de tratamento de doenças inflamatórias
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
BR112013029902A2 (pt) produção de alta pureza de proteínas de múltiplas subunidades, tal como anticorpos, em micróbios transformados, tal como pichia pastoris